For the year ending 2025-12-31, ALNY has $4,966,331K in assets. $4,177,155K in debts. $1,657,250K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 1,657,250 | |||
| Marketable debt securities | 1,251,234 | |||
| Marketable equity securities | 0 | |||
| Accounts receivable, net | 777,567 | |||
| Inventory | 82,719 | |||
| Prepaid expenses and other current assets | 281,892 | |||
| Total current assets | 4,050,662 | |||
| Property, plant and equipment, net | 513,147 | |||
| Operating lease right-of-use assets | 194,916 | |||
| Deferred tax assets | 125,975 | |||
| Restricted investments | 22,170 | |||
| Other assets | 59,461 | |||
| Total assets | 4,966,331 | |||
| Accounts payable | 115,721 | |||
| Accrued expenses | 1,080,197 | |||
| Operating lease liabilities | 45,518 | |||
| Deferred revenue | 4,845 | |||
| Liabilities related to the sale of future royalties and development funding | 220,068 | |||
| Development derivative liability | 0 | |||
| Total current liabilities | 1,466,349 | |||
| Operating lease liabilities, net of current portion | 225,087 | |||
| Convertible debt | 1,007,784 | |||
| Liabilities related to the sale of future royalties and development funding, net of current portion | 1,470,341 | |||
| Development derivative liability, net of current portion | 0 | |||
| Other liabilities | 7,594 | |||
| Total liabilities | 4,177,155 | |||
| Common stock, 0.01 par value per share, 250,000 shares authorized as of december31, 2025 and december31, 2024, respectively 132,376 shares issued and outstanding as of december31, 2025 129,294 shares issued and outstanding as of december31, 2024 | 1,324 | |||
| Additional paid-in capital | 7,510,473 | |||
| Accumulated other comprehensive loss | -20,097 | |||
| Accumulated deficit | -6,702,524 | |||
| Total stockholders' equity | 789,176 | |||
| Total liabilities and stockholders' equity | 4,966,331 | |||
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY)